The drug candidate AKP02G2 combines calcipotriol and betamethasone and is based on
AKP02G2 is a further development of AKP02, which underwent a clinical phase III study in 2022. Experience from this study, together with development work and preclinical studies conducted in 2023, has led to a new formulation that is expected to produce an improved effect compared to AKP02.
The registration-based Phase III study with AKP02G2 is planned to include 294 patients and will be conducted by
The aim of the Phase III study with AKP02G2 is to demonstrate good therapeutic efficacy in comparison to Enstilar, in the treatment of mild to moderate plaque psoriasis on both the body and scalp. Enstilar is a commonly prescribed preparation in foam form for the topical treatment of psoriasis and contains the same combination of active substances as AKP02G2.
A prerequisite for the Phase III study to be able to start according to plan is that
Publication
The information was provided for publication by Lipidor’s CEO on 20th December 2023 at
© Modular Finance, source